Hospital

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.

Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.

As evidence grows for psilocybin-assisted therapy’s effectiveness in treating mental health and addiction, efforts are increasingly focused on ensuring equitable access—particularly for underserved communities disproportionately affected by systemic barriers and public health crises.

New research highlights the need for evidence-based buspirone use in psychiatric settings, revealing high off-label prescriptions and suboptimal dosing practices.

Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.

Research reveals a significant link between maternal anemia and increased risk of congenital heart defects in infants, highlighting the need for effective prevention strategies.

The American Lung Association is raising awareness about updated pneumococcal vaccine guidelines, emphasizing prevention and patient education for at-risk populations.

New research shows adults with RSV-ARI may face significantly higher mortality and health complications, emphasizing the need for targeted vaccination strategies.

Douglas Adkins, MD shares key data and findings from the phase 3 KEYNOTE-689 study.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.

Explore the role of JAK inhibitors in myelofibrosis treatment, focusing on optimizing dosages and managing adverse effects for better patient outcomes.

Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.

Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.

Artificial intelligence (AI) models enhance cancer cachexia detection, improving accuracy in predicting muscle atrophy and patient outcomes through advanced biomarker analysis.

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

No matter what role you are in as a pharmacist, no matter where you work or how long you have been practicing, understand that making a difference in the life of a patient matters.

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.

The study found that 4 weeks was the ideal time point to test for cTDNA.

Ochsner Children’s Hospital, in partnership with ISMP, has launched a fellowship to advance pediatric medication safety through hands-on training in key competencies, national safety strategies, interdisciplinary collaboration, and innovative tools such as AI and data dashboards.

AI may help to accurately classify pediatric sarcoma subtypes using digitized pathology images, potentially improving diagnosis and treatment accessibility across diverse health care settings.

Pharmacists play a crucial role in advancing biosimilar adoption through targeted education and by addressing misconceptions about safety and efficacy.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.

NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.